Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PASDAS beats DAS28 in measuring psoriatic arthritis treat-to-target success

Key clinical point: The Psoriatic Arthritis Disease Activity Score (PASDAS) may be a better tool than the Disease Activity Score in 28 joints (DAS28) in assessing treat-to-target success in patients with psoriatic arthritis.

Major finding: Fewer patients reached low disease activity according to PASDAS (77.4%) versus DAS28 (53.1%).

Study details: Prospective cohort study (n = 855).

Disclosures: The study received no funding. The presenter had no relevant financial disclosures.

Citation:

Mulder M et al. GRAPPA 2020 Virtual Annual Meeting.